New York is currently home to 4447 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Helmsley 3.0: Abbreviated MRE
Recruiting
The purpose of our study is to compare an abbreviated magnetic resonance imaging (MRI) of the bowel or magnetic resonance enterography (MRE) protocol to a conventional, standard of care MRE in children and adults with Crohn's Disease.
Gender:
ALL
Ages:
10 years and above
Trial Updated:
12/11/2024
Locations: NYU Langone, New York, New York
Conditions: Crohn's Disease
RESTORE: An RCT to Evaluate the Efficacy of the Revi System
Recruiting
The Revi System is indicated for the treatment of patients with symptoms of urgency incontinence alone or in combination with urinary urgency.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
12/11/2024
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Urinary Urge Incontinence
The Study of Immunization in People Living With HIV Undergoing an ATI for Elicitation of VRC01-lineage Antibodies
Recruiting
This is a multicenter controlled interventional trial. This phase 1 trial is the first study to assess 426c.Mod.Core-C4b adjuvanted with 3M-052-AF + aluminum hydroxide suspension (Alum) in people living with HIV (PLWH).
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
12/11/2024
Locations: Columbia P&S CRS Site#30329, New York, New York
Conditions: Chronic HIV Infection
A Study of an MMSET Inhibitor in Patients with Relapsed and Refractory Multiple Myeloma
Recruiting
A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/11/2024
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Multiple Myeloma, Myeloma, Myeloma Multiple
ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND)
Recruiting
ASCEND researchers are partnering with families of children who receive extracorporeal membrane oxygenation (ECMO) after a sudden failure of breathing named pediatric acute respiratory distress syndrome (PARDS). ECMO is a life support technology that uses an artificial lung outside of the body to do the lung's work. ASCEND has two objectives. The first objective is to learn more about children's abilities and quality of life among ECMO-supported children in the year after they leave the pediatr... Read More
Gender:
ALL
Ages:
Between 14 days and 20 years
Trial Updated:
12/11/2024
Locations: John R. Oishei Children's Hospital, Buffalo, New York
Conditions: Acute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation
A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Recruiting
Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-655, determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ALK- positive (ALK+) NSCLC and other solid tumors. Phase 1 will evaluate the overall safety and tolerability of NVL-655 and will determine the RP2D and, if applicable, the MTD of NVL-655 in patients with advanced ALK+ solid tumors. Phase 2 will determine the objective response rat... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
12/11/2024
Locations: Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York, New York
Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor
Decreasing Polypharmacy in Older Adults with Curable Cancers Trial
Recruiting
This is a single-site cluster-randomized trial to assess efficacy and implementation outcomes of deprescribing interventions in 72 older adults with polypharmacy (PP) and curable cancers initiating chemotherapy. Oncologists (as the cluster) will enroll 6 patients each and will be randomized to either a pharmacist-led deprescribing intervention or patient education intervention. Initial focus groups with oncologists, nurses, pharmacists, primary care physicians, and patients will provide data for... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
12/11/2024
Locations: University of Rochester, Rochester, New York
Conditions: Cancer
Study of Rituximab or Tocilizumab for Patients with Steroid-Dependent Immune-Related Adverse Events (irAEs)
Recruiting
The purpose of this study is to examine how effective rituximab or tocilizumab are in treating side effects for people who are receiving immunotherapy treatment requiring prolonged steroid use. Immune-related side effects are caused by the activation of the immune system. Because rituximab and tocilizumab have been shown to effectively in treating other diseased that involve immune system activation, this study seeks to evaluate how effective they will be in treating immune-related side effects... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/11/2024
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Immune-related Adverse Events, Advanced Solid Tumor
Quality of Life (QoL) Assessment in Cancer Patients and Survivors With Dermatologic Conditions Using Dermatologic QoL Instruments
Recruiting
The purpose of this study is to see how skin conditions that are related to different kinds of cancer or cancer treatments affect a patient's overall well-being. Skin conditions are common in cancer patients and survivors. Sometimes, the skin condition is directly related to the cancer. Other times, these conditions are a side effect of cancer treatment. Patients in the study will be asked to fill out at least one questionnaire about how they feel about their skin condition. If the patient needs... Read More
Gender:
ALL
Ages:
3 years and above
Trial Updated:
12/11/2024
Locations: Memorial Sloan Kettering Westchester, Harrison, New York
Conditions: Cancer, Dermatologic Conditions
Clinical and Neuropsychological Investigations in Batten Disease
Recruiting
This study aims to assess the natural history of Batten disease (Neuronal Ceroid Lipofuscinosis) by obtaining information about the motor, behavioral, and functional capabilities of individuals with Batten disease. This study will also refine and validate the Unified Batten Disease Rating Scale (UBDRS) as a clinical rating instrument for Batten disease.
Gender:
ALL
Ages:
All
Trial Updated:
12/11/2024
Locations: University of Rochester, Rochester, New York
Conditions: Neuronal Ceroid Lipofuscinosis, Neuronal Ceroid Lipofuscinosis CLN1, Neuronal Ceroid Lipofuscinosis CLN2, Neuronal Ceroid Lipofuscinosis CLN3, Neuronal Ceroid Lipofuscinosis CLN5, Neuronal Ceroid Lipofuscinosis CLN6, Neuronal Ceroid Lipofuscinosis CLN7, Neuronal Ceroid Lipofuscinosis CLN8, Neuronal Ceroid Lipofuscinosis CLN10, Batten Disease
A Phase I-II Study of High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Abatacept for the Prevention of Graft-Versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Recruiting
The study will be conducted in two phases. The phase I portion will employ a 3+3 dose-escalation design to define the maximum tolerated dose (MTD) of abatacept added to PTCy and bortezomib following HSCT. The phase II portion will consist of two single-arm, open-label, optimal 2-stage Simon design studies conducted in two separate strata for HLA-matched and HLA-mismatched donor transplants.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/10/2024
Locations: Zuckerberg Cancer Center, Lake Success, New York
Conditions: Graft Vs Host Disease
Spastic Paraplegia - Centers of Excellence Research Network
Recruiting
The Spastic Paraplegia - Centers of Excellence Research Network (SP-CERN) is a collaborative research consortium dedicated to advancing the understanding, diagnosis, and treatment of hereditary spastic paraplegia (HSP) and primary lateral sclerosis (PLS). Aims of the consortium are to a) perform natural history studies of HSP subtypes, b) discover and validate biomarkers and clinician- and patient-reported outcome measures, c) uncover HSP's molecular pathophysiology and develop rational therapeu... Read More
Gender:
ALL
Ages:
All
Trial Updated:
12/10/2024
Locations: Columbia University - Irving Medical Center, New York, New York
Conditions: Hereditary Spastic Paraplegia, Primary Lateral Sclerosis, SPG4, SPG5A, Spastic Paraplegia 4, Spastic Paraplegia 5A, Early Onset Hereditary Spastic Paraplegia, Neuromuscular Diseases, Spastic Paraplegia, Hereditary